Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

 
• By Joseph Haas

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

3d illustration of red blood cells in the artery
Six partner companies hope to derive a plasma-based COVID therapy from donors who survived the virus

More from COVID-19

More from Scrip